Dramatic Reduction in Tumor Size During 5 Months of Pazopanib Therapy in Combination With Ifosfamide, Carboplatin, and Etoposide in an Early Infant With Progressive Soft Tissue Sarcoma

Tatsuo Watanabe,Takashi Kurata,Kenji Sano,Shigeru Suzuki,Tomoki Kaneko,Mitsuo Motobayashi,Tomonari Shigemura,Takuro Sumi,Kenichi Koike,Yozo Nakazawa

Dramatic Reduction in Tumor Size During 5 Months of Pazopanib Therapy in Combination With Ifosfamide, Carboplatin, and Etoposide in an Early Infant With Progressive Soft Tissue Sarcoma

2017

Tatsuo Watanabe
Takashi Kurata
Kenji Sano
Shigeru Suzuki
Tomoki Kaneko
Mitsuo Motobayashi
Tomonari Shigemura
Takuro Sumi
Kenichi Koike
Yozo Nakazawa

To the Editor:Pazopanib is a multikinase inhibitor, inhibiting the signal transduction pathways of vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors, and the stem cell factor receptor.1 Pazopanib monotherapy improved progression-free survival in adult pa

Keywords:

Pathology
Ifosfamide
Etoposide
Carboplatin
Stem cell factor
Soft tissue sarcoma
Cancer research
Vascular endothelial growth factor
Medicine
Pazopanib
Growth factor receptor
Surgery

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations